Merck and Moderna: mRNA Vaccine Reduces Risk of Melanoma Recurrence by 42%

Merck and Moderna announced the full results of a trial of an experimental vaccine against melanoma, and Reuters reported that it reduces the risk of death or disease recurrence by 42% when used with a common immunotherapy. Sources say the result is important for patients with this type of cancer, while Moderna's shares fell after the data circulated on social media.

AI-written summary of 4 sources; every verified point is backed by a verbatim quote. How Iyan works

• The two companies announced the full results of the trial on Thursday, a trial of an experimental cancer vaccine that has been closely followed.

  «The drug makers Merck and Moderna announced on Thursday the full results of a closely watched trial of an experim»

  The New York Times
• The mRNA-based vaccine also reduced the spread of the disease by 38% when used with a common immunotherapy.

  «cut the risk of death ‌or recurrence of melanoma by 42% and disease spread by 38%»

  Reuters
• CNN described the vaccine as possibly the first personalized mRNA-based cancer vaccine to succeed in a late-stage trial in patients with melanoma.

  «what could be the first personalized mRNA cancer vaccine had succeeded in a late-stage clinical trial in melanoma»

  CNN on MSN
• Moderna's shares fell sharply after data on the cancer vaccine circulated on social media.

  «Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media»

  WSJ

Iyan — See it for yourself. What changed in your world today, why it matters, and how we know.
How it works • Privacy • Terms